Interstitial Pneumonitis from Treatment with Gemcitabine
- 1 September 2014
- journal article
- case report
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 49 (9) , 847-850
Abstract
Introduction: The use of gemcitabine may lead to numerous adverse effects ranging from mild to very severe, such as interstitial pneumonitis. The diagnosis of this complication is based on multiple laboratory findings, radiographic evidence, and high clinical suspicion. Presented is a case report of a patient who met these criteria and had onset consistent with drug-induced interstitial pneumonitis. Case Presentation: A 76-year-old White female was treated with gemcitabine for pancreatic cancer. Two months after the initiation of therapy, she was admitted to the hospital for worsening dyspnea and cough. High clinical suspicion, bilateral interstitial opacities on chest x-ray, worsening pulmonary status, and onset 2 months after initiation of therapy led to the diagnosis of gemcitabine-induced interstitial pneumonitis. Steroid therapy with prednisone was initiated, and the patient's clinical symptoms and radiographic findings improved. Discussion: Gemcitabine-induced interstitial pneumonitis is well described in the literature. It is a rare but serious complication associated with gemcitabine therapy in which patients present with worsening dyspnea. Most patients only require supportive care and discontinuation of the drug for treatment, but in severe cases supplemental oxygen and steroid therapy must be used before resolution of symptoms. It is important to obtain an accurate medication history to evaluate for other potentially pulmonary toxic medications. Radiographic findings such as bilateral infiltrates should be completely resolved after therapy. Conclusion: Radiographic findings, clinical symptoms, and clinical suspicion can lead to early recognition of interstitial pneumonitis from gemcitabine. Physician awareness of this adverse effect and early recognition are keys to providing prompt treatment in resolving symptoms and decreasing mortality.Keywords
This publication has 16 references indexed in Scilit:
- Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancerJournal of Cancer Research and Clinical Oncology, 2011
- Amiodarone-induced pulmonary toxicity mimicking acute pulmonary edemaJournal of Cardiovascular Medicine, 2011
- Gemcitabine Pulmonary Toxicity in Ovarian CancerThe Oncologist, 2008
- Amiodarone‐induced pulmonary toxicityBritish Journal of Clinical Pharmacology, 2008
- Chemotherapy-induced lung diseaseClinics in Chest Medicine, 2004
- Gemcitabine-Induced Pulmonary ToxicityAmerican Journal of Clinical Oncology, 2002
- Gemcitabine—a safety reviewAnti-Cancer Drugs, 1998
- Cardiac arrest in seattle: Conventional versus amiodarone drug evaluation (the CASCADE study)The American Journal of Cardiology, 1991
- Clinical features of amiodarone-induced pulmonary toxicity.Circulation, 1990
- Amiodarone Pulmonary ToxicityChest, 1988